title: Influence of body mass index on survival in veterans with multiple myeloma.
abstract: OBJECTIVE
  We investigated the association between body mass index (BMI) at the time of multiple myeloma (MM) diagnosis and overall survival in a cohort of patients within the Veterans Health Administration system. We also evaluated the association between weight loss in the year prior to diagnosis and survival.
  
  
  METHODS
  Prospective analysis was performed on a retrospectively assembled cohort of 2,968 U.S. veterans diagnosed and treated for MM between September 1, 1999, and September 30, 2009, with follow-up information through October 22, 2011. Cox modeling controlling for patient- and disease-related prognostic variables was used to analyze the data.
  
  
  RESULTS
  Underweight patients (BMI <18.5 kg/m2) had increased mortality, whereas patients who were overweight (BMI 25-29.9 kg/m2) and obese (BMI ≥30 kg/m2) had lower mortality compared with healthy-weight patients (BMI 18.5-24.9 kg/m2). Weight loss ≥10% of baseline in the year before diagnosis was also associated with increased mortality and made the association between increased BMI and survival nonsignificant.
  
  
  CONCLUSIONS
  Disease-related weight loss may be an important and heretofore unknown indicator of poor prognosis in MM. Assessment of weight loss prior to MM diagnosis should become a standard component of the clinical history in patients with newly diagnosed MM. Further research may identify relationships between disease-related weight loss and currently used prognostic factors in MM, further defining the role of this clinical factor in prognostic stratification.
authors.affiliation: Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, Missouri, USA;
authors.forename: Tracey S
authors.initials: TS
authors.lastname: Beason
authors.forename: Su-Hsin
authors.initials: SH
authors.lastname: Chang
authors.forename: Kristen M
authors.initials: KM
authors.lastname: Sanfilippo
authors.forename: Suhong
authors.initials: S
authors.lastname: Luo
authors.forename: Graham A
authors.initials: GA
authors.lastname: Colditz
authors.forename: Ravi
authors.initials: R
authors.lastname: Vij
authors.forename: Michael H
authors.initials: MH
authors.lastname: Tomasson
authors.forename: John F
authors.initials: JF
authors.lastname: Dipersio
authors.forename: Keith
authors.initials: K
authors.lastname: Stockerl-Goldstein
authors.forename: Arun
authors.initials: A
authors.lastname: Ganti
authors.forename: Tanya
authors.initials: T
authors.lastname: Wildes
authors.forename: Kenneth R
authors.initials: KR
authors.lastname: Carson
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015992:Body Mass Index; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000401:mortality* / Q000473:pathology; D009765:Obesity / Q000401:mortality / Q000473:pathology*; D011379:Prognosis; D016016:Proportional Hazards Models; D012307:Risk Factors; D014728:Veterans; D015431:Weight Loss
keywords: Body mass index; Mortality; Multiple myeloma; Obesity; Overweight; Survival
references.citation: Cancer Detect Prev. 1999;23(3):226-31
references.pmid: 10337001
references.citation: Blood. 2012 Jan 5;119(1):49-54
references.pmid: 22049518
references.citation: J Clin Oncol. 2005 May 20;23(15):3412-20
references.pmid: 15809451
references.citation: Hematol J. 2003;4(6):379-98
references.pmid: 14671610
references.citation: Lancet Oncol. 2010 Aug;11(8):741-52
references.pmid: 20594911
references.citation: Med Care. 2009 Jan;47(1):125-8
references.pmid: 19106741
references.citation: Blood. 1992 Aug 1;80(3):733-7
references.pmid: 1638024
references.citation: Oncologist. 2010;15(10):1083-101
references.pmid: 20930095
references.citation: Cancer. 1975 Sep;36(3):842-54
references.pmid: 1182674
references.citation: J Occup Environ Med. 2010 Jan;52(1):39-53
references.pmid: 20042883
references.citation: Br J Haematol. 1996 May;93(2):352-9
references.pmid: 8639428
references.citation: N Engl J Med. 1993 Sep 30;329(14):987-94
references.pmid: 8141877
references.citation: JAMA. 2010 Jan 20;303(3):235-41
references.pmid: 20071471
references.citation: Mayo Clin Proc. 2003 Jan;78(1):21-33
references.pmid: 12528874
references.citation: Eur J Cancer. 2011 Jul;47(11):1606-15
references.pmid: 21354783
references.citation: J Clin Oncol. 1995 Mar;13(3):575-82
references.pmid: 7884418
references.citation: J Natl Cancer Inst. 1980 Jul;65(1):25-32
references.pmid: 6930515
references.citation: Cancer Res. 2000 Oct 1;60(19):5488-93
references.pmid: 11034092
references.citation: J Clin Epidemiol. 1993 Oct;46(10):1075-9; discussion 1081-90
references.pmid: 8410092
references.citation: Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2348-54
references.pmid: 17164355
references.citation: Asian Pac J Cancer Prev. 2006 Oct-Dec;7(4):575-81
references.pmid: 17250430
references.citation: N Engl J Med. 2006 Aug 24;355(8):763-78
references.pmid: 16926275
references.citation: J Clin Oncol. 2002 Apr 15;20(8):2101-8
references.pmid: 11956271
references.citation: Blood. 2012 Sep 13;120(11):2290-6
references.pmid: 22740447
references.citation: J Clin Oncol. 2012 Sep 10;30(26):3217-22
references.pmid: 22649138
references.citation: PLoS Comput Biol. 2010 Nov 04;6(11):e1000968
references.pmid: 21079667
references.citation: Blood. 2003 Jun 1;101(11):4569-75
references.pmid: 12576322
references.citation: BMJ. 2007 Dec 1;335(7630):1134
references.pmid: 17986716
references.citation: Int J Cancer. 2007 Oct 1;121(7):1564-70
references.pmid: 17443495
references.citation: Leukemia. 1997 Oct;11(10):1661-4
references.pmid: 9324286
references.citation: N Engl J Med. 2003 Apr 24;348(17):1625-38
references.pmid: 12711737
references.citation: Popul Health Metr. 2006 Apr 10;4:2
references.pmid: 16606453